Description
Anti-VEGF-D Antibody, Non-Fucosylated (BioBet-892ZP) is a humanized monoclonal IgG antibody against VEGF-D. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Cancer
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced VEGF-D antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
FIGF
Full Name
c-fos induced growth factor (vascular endothelial growth factor D)
Background
The protein encoded by this gene is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family and is active in angiogenesis, lymphangiogenesis, and endothelial cell growth. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms which bind and activate VEGFR-2 and VEGFR-3 receptors. This protein is structurally and functionally similar to vascular endothelial growth factor C. Read-through transcription has been observed between this locus and the upstream PIR (GeneID 8544) locus.
Alternative Names
FIGF; c-fos induced growth factor (vascular endothelial growth factor D); VEGFD; VEGF-D; vascular endothelial growth factor D
Gene ID
2277
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with VEGFD include Anal Canal Squamous Cell Carcinoma and Kidney Angiomyolipoma.
Related Pathways
Its related pathways are HIF1Alpha Pathway and Signaling by GPCR.
Function
Growth factors play a role in angiogenesis, lymphangiogenesis and endothelial cell growth, stimulate their proliferation and migration, and affect the permeability of blood vessels. It is possible that the formation of veins and lymphatic vasculature during embryogenesis also plays a role in the maintenance of differentiated lymphatic endothelium in adults. Binds and activates VEGFR-2 (KDR/FLK1) and VEGFR-3 (FLT4) receptors.
Post-translational modifications
Undergoes a complex proteolytic maturation which generates a variety of processed secreted forms with increased activity toward VEGFR-3 and VEGFR-2. VEGF-D first form an antiparallel homodimer linked by disulfide bonds before secretion. The fully processed VEGF-D is composed mostly of two VEGF homology domains (VHDs) bound by non-covalent interactions.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
BioBet-892ZP
Description
The humanized VEGF-D antibody are useful for modulating angiogenesis and lymphangiogenesis in a subject.
Antibody Indication
Cancer
